GlaxoSmithKline_NNP 178_CD Taxation_NNP information_NN for_IN shareholders_NNS Information_NN for_IN shareholders_NNS Stamp_NNP duty_NN UK_NNP stamp_VB duty_NN or_CC stamp_VB duty_NN reserve_NN tax_NN SDRT_NNP will_MD ,_, subject_JJ to_TO A_DT summary_NN of_IN the_DT main_JJ tax_NN consequences_NNS for_IN holders_NNS of_IN shares_NNS certain_JJ exemptions_NNS ,_, be_VB payable_JJ on_IN the_DT purchase_NN of_IN shares_NNS at_IN a_DT and_CC ADRs_NNS who_WP are_VBP citizens_NNS or_CC residents_NNS of_IN the_DT UK_NNP or_CC the_DT USA_NNP is_VBZ rate_NN of_IN 0.5_CD per_IN cent_NN of_IN the_DT purchase_NN price_NN ._.
There_EX is_VBZ a_DT minimum_NN set_VBN out_RP below_IN ._.
It_PRP is_VBZ not_RB a_DT complete_JJ analysis_NN of_IN all_PDT the_DT possible_JJ tax_NN charge_NN of_IN 5_CD where_WRB a_DT stamp_NN duty_NN liability_NN arises_VBZ ._.
consequences_NNS of_IN purchase_NN or_CC ownership_NN of_IN these_DT securities_NNS ._.
It_PRP is_VBZ intended_VBN only_RB as_IN a_DT general_JJ guide_NN ._.
Holders_NNS are_VBP advised_VBN to_TO consult_VB US_NNP shareholders_NNS their_PRP$ advisers_NNS with_IN respect_NN to_TO the_DT tax_NN consequences_NNS of_IN the_DT purchase_NN and_CC ownership_NN of_IN their_PRP$ shares_NNS or_CC ADRs_NNS ,_, and_CC the_DT The_DT following_NN is_VBZ a_DT summary_NN of_IN certain_JJ UK_NNP taxation_NN and_CC USA_NNP consequences_NNS under_IN state_NN and_CC local_JJ tax_NN laws_NNS in_IN the_DT USA_NNP and_CC federal_JJ income_NN tax_NN considerations_NNS that_WDT may_MD be_VB relevant_JJ to_TO a_DT the_DT implications_NNS of_IN the_DT new_JJ UK_NNP US_NNP Income_NNP Tax_NNP convention_NN ._.
US_NNP holder_NN of_IN shares_NNS or_CC ADRs_NNS ._.
This_DT summary_NN only_RB applies_VBZ to_TO a_DT shareholder_NN that_WDT holds_VBZ shares_NNS or_CC ADRs_NNS as_IN capital_NN assets_NNS ,_, is_VBZ a_DT This_DT statement_NN is_VBZ based_VBN upon_IN UK_NNP and_CC US_NNP tax_NN laws_NNS and_CC practices_NNS citizen_NN or_CC resident_NN of_IN the_DT USA_NNP or_CC a_DT domestic_JJ corporation_NN or_CC that_DT at_IN the_DT date_NN of_IN this_DT report_NN ._.
is_VBZ otherwise_RB subject_JJ to_TO United_NNP States_NNPS federal_JJ income_NN taxation_NN on_IN The_DT new_JJ UK_NNP US_NNP Income_NNP Tax_NNP Convention_NNP came_VBD into_IN force_NN on_IN a_DT net_JJ income_NN basis_NN in_IN respect_NN of_IN the_DT shares_NNS or_CC ADRs_NNS ,_, and_CC is_VBZ not_RB 31st_JJ March_NNP 2003_CD ._.
The_DT provisions_NNS of_IN the_DT new_JJ treaty_NN apply_VB for_IN UK_NNP resident_NN in_IN the_DT UK_NNP for_IN UK_NNP tax_NN purposes_NNS and_CC does_VBZ not_RB hold_VB shares_NNS tax_NN purposes_NNS from_IN 1st_CD April_NNP 2003_CD UK_NNP Corporation_NNP Tax_NNP ,_, 6th_JJ April_NNP for_IN the_DT purposes_NNS of_IN a_DT trade_NN ,_, profession_NN or_CC vocation_NN that_WDT is_VBZ carried_VBN 2003_CD UK_NNP Income_NNP Tax_NNP and_CC Capital_NNP Gains_NNS Tax_NNP and_CC 1st_CD May_NNP 2003_CD on_IN in_IN the_DT UK_NNP through_IN a_DT branch_NN or_CC agency_NN ._.
For_IN US_NNP tax_NN purposes_NNS ,_, the_DT provisions_NNS of_IN the_DT new_JJ treaty_NN apply_VB from_IN 1st_CD May_NNP 2003_CD Withholding_NNP Taxes_NNS and_CC Taxation_NNP of_IN dividends_NNS 1st_CD January_NNP 2004_CD all_DT other_JJ US_NNP taxes_NNS ._.
However_RB ,_, holders_NNS of_IN shares_NNS The_DT gross_JJ amount_NN of_IN dividends_NNS received_VBD including_VBG amounts_NNS in_IN or_CC ADRs_NNS have_VBP the_DT ability_NN to_TO elect_VB to_TO continue_VB to_TO use_VB the_DT respect_NN of_IN associated_VBN tax_NN credit_NN and_CC UK_NNP withholding_NN tax_NN is_VBZ treated_VBN provisions_NNS of_IN the_DT previous_JJ treaty_NN for_IN 12_CD months_NNS following_VBG the_DT as_IN foreign_JJ source_NN dividend_NN income_NN for_IN US_NNP tax_NN purposes_NNS ._.
It_PRP is_VBZ not_RB new_JJ treatys_NNS entry_NN into_IN force_NN ._.
An_DT election_NN must_MD be_VB made_VBN in_IN eligible_NN for_IN the_DT dividend_NN received_VBN deduction_NN allowed_VBN to_TO US_NNP advance_NN of_IN the_DT first_JJ event_NN to_TO which_WDT the_DT new_JJ treaty_NN would_MD apply_VB ._.
Dividends_NNS on_IN ADRs_NNS are_VBP payable_JJ in_IN US_NNP dollars_NNS :_: dividends_NNS on_IN shares_NNS are_VBP payable_JJ in_IN Sterling_NNP ._.
Dividends_NNS paid_VBN in_IN US_NNP holders_NNS of_IN ADRs_NNS generally_RB will_MD be_VB treated_VBN as_IN the_DT owners_NNS of_IN pounds_NNS Sterling_NNP will_MD be_VB included_VBN in_IN income_NN in_IN the_DT US_NNP dollar_NN the_DT underlying_JJ shares_NNS for_IN the_DT purposes_NNS of_IN the_DT current_JJ USA_NNP UK_NNP amount_NN calculated_VBN by_IN reference_NN to_TO the_DT exchange_NN rate_NN on_IN the_DT day_NN double_RB taxation_NN conventions_NNS relating_VBG to_TO income_NN and_CC gains_VBZ the_DT dividends_NNS are_VBP received_VBN by_IN the_DT holder_NN ._.
Subject_JJ to_TO certain_JJ Income_NN Tax_NNP Convention_NNP ,_, estate_NN and_CC gift_NN taxes_NNS Estate_NNP and_CC Gift_NNP exceptions_NNS ,_, an_DT individual_JJ eligible_JJ US_NNP holder_NN will_MD be_VB subject_JJ to_TO US_NNP Tax_NNP Convention_NNP and_CC for_IN the_DT purposes_NNS of_IN the_DT US_NNP Internal_NNP Revenue_NNP taxation_NN at_IN a_DT maximum_NN rate_NN of_IN 15_CD per_IN cent_NN in_IN respect_NN of_IN qualified_VBN Code_NNP of_IN 1986_CD ,_, as_IN amended_VBN the_DT Code_NNP ._.
Shareholders_NNS are_VBP advised_VBN to_TO The_DT following_JJ analysis_NN deals_NNS with_IN dividends_NNS paid_VBN after_IN 6th_JJ April_NNP consult_VB their_PRP$ own_JJ Tax_NNP Advisers_NNPS to_TO confirm_VB their_PRP$ eligibility_NN ._.
1999_CD when_WRB Advance_NNP Corporation_NNP Tax_NNP ACT_NNP was_VBD abolished_VBN ._.
Taxation_NNP of_IN capital_NN gains_NNS UK_NNP shareholders_NNS Generally_RB ,_, US_NNP holders_NNS will_MD not_RB be_VB subject_JJ to_TO UK_NNP capital_NN gains_NNS tax_NN ,_, but_CC will_MD be_VB subject_JJ to_TO US_NNP tax_NN on_IN capital_NN gains_NNS realized_VBN on_IN the_DT sale_NN Taxation_NNP of_IN dividends_NNS or_CC other_JJ disposal_NN of_IN shares_NNS or_CC ADRs_NNS ._.
From_IN 6th_JJ April_NNP 1999_CD ,_, the_DT rate_NN of_IN tax_NN credits_NNS was_VBD reduced_VBN to_TO one_CD ninth_JJ ._.
As_IN a_DT result_NN of_IN compensating_VBG reductions_NNS in_IN the_DT rate_NN of_IN tax_NN Estate_NNP and_CC gift_NN taxes_NNS on_IN dividend_NN income_NN ,_, there_EX is_VBZ no_DT increase_NN in_IN the_DT tax_NN borne_VBN by_IN UK_NNP Under_IN the_DT Estate_NNP and_CC Gift_NNP Tax_NNP Convention_NNP ,_, a_DT US_NNP shareholder_NN resident_NN individual_JJ shareholders_NNS ._.
Tax_NNP credits_NNS are_VBP ,_, however_RB ,_, no_DT is_VBZ not_RB generally_RB subject_JJ to_TO UK_NNP inheritance_NN tax_NN ._.
longer_RB repayable_JJ to_TO shareholders_NNS with_IN a_DT tax_NN liability_NN of_IN less_JJR than_IN the_DT associated_VBN tax_NN credit_NN ._.
Stamp_NN duty_NN UK_NNP stamp_VB duty_NN or_CC SDRT_NNP will_MD ,_, subject_JJ to_TO certain_JJ exemptions_NNS ,_, be_VB Taxation_NNP of_IN capital_NN gains_NNS payable_JJ on_IN any_DT issue_NN or_CC transfer_NN of_IN shares_NNS to_TO the_DT ADR_NNP custodian_NN UK_NNP shareholders_NNS may_MD be_VB liable_JJ for_IN UK_NNP tax_NN on_IN gains_NNS on_IN the_DT or_CC depository_NN at_IN a_DT rate_NN of_IN 1.5_CD per_IN cent_NN of_IN their_PRP$ price_NN if_IN issued_VBN ,_, disposal_NN of_IN shares_NNS or_CC ADRs_NNS ._.
They_PRP may_MD also_RB be_VB entitled_VBN to_TO the_DT amount_NN of_IN any_DT consideration_NN provided_VBN if_IN transferred_VBN on_IN indexation_NN relief_NN and_CC taper_VB relief_NN on_IN such_JJ sales_NNS ._.
Indexation_NN relief_NN sale_NN ,_, or_CC their_PRP$ value_NN if_IN transferred_VBN for_IN no_DT consideration_NN ._.
is_VBZ calculated_VBN on_IN the_DT market_NN value_NN of_IN shares_NNS at_IN 31st_CD March_NNP 1982_CD and_CC on_IN the_DT cost_NN of_IN any_DT subsequent_JJ purchases_NNS from_IN the_DT date_NN of_IN No_DT SDRT_NN would_MD be_VB payable_JJ on_IN the_DT transfer_NN of_IN an_DT ADR_NNP ._.
Indexation_NN relief_NN for_IN individual_JJ shareholders_NNS stamp_VBP duty_NN should_MD be_VB payable_JJ on_IN the_DT transfer_NN of_IN an_DT ADR_NNP ceased_VBD on_IN 5th_JJ April_NNP 1998_CD ._.
Taper_VB relief_NN is_VBZ available_JJ to_TO individual_JJ provided_VBN that_IN the_DT instrument_NN of_IN transfer_NN is_VBZ executed_VBN and_CC remains_VBZ shareholders_NNS who_WP hold_VBP or_CC are_VBP deemed_VBN to_TO hold_VB shares_NNS for_IN at_IN least_JJS at_IN all_DT times_NNS outside_IN the_DT UK_NNP ._.
Any_DT stamp_NN duty_NN on_IN the_DT transfer_NN of_IN three_CD years_NNS before_IN they_PRP are_VBP sold_VBN ._.
an_DT ADR_NNP would_MD be_VB payable_JJ at_IN a_DT rate_NN of_IN 0.5_CD per_IN cent_NN of_IN the_DT consideration_NN for_IN the_DT transfer_NN ._.
Any_DT sale_NN of_IN the_DT underlying_JJ shares_NNS Inheritance_NNP tax_NN would_MD result_VB in_IN liability_NN to_TO UK_NNP stamp_VB duty_NN or_CC ,_, as_IN the_DT case_NN may_MD be_VB ,_, Individual_JJ shareholders_NNS may_MD be_VB liable_JJ to_TO inheritance_NN tax_NN on_IN the_DT SDRT_NNP at_IN a_DT rate_NN of_IN 0.5_CD per_IN cent_NN ._.
There_EX is_VBZ a_DT minimum_JJ charge_NN of_IN transfer_NN of_IN shares_NNS or_CC ADRs_NNS ._.
Tax_NNP may_MD be_VB charged_VBN on_IN the_DT amount_NN 5_CD where_WRB a_DT stamp_NN duty_NN liability_NN arises_VBZ ._.
by_IN which_WDT the_DT value_NN of_IN the_DT shareholder_NN 's_POS estate_NN is_VBZ reduced_VBN as_IN a_DT result_NN of_IN any_DT transfer_NN by_IN way_NN of_IN gift_NN or_CC other_JJ disposal_NN at_IN less_JJR than_IN full_JJ market_NN value_NN ._.
Such_JJ a_DT gift_NN or_CC other_JJ disposal_NN is_VBZ subject_JJ to_TO both_DT UK_NNP inheritance_NN tax_NN and_CC US_NNP estate_NN or_CC gift_NN tax_NN ._.
The_DT Estate_NNP and_CC Gift_NNP Tax_NNP Convention_NNP would_MD generally_RB provide_VB for_IN tax_NN paid_VBN in_IN the_DT USA_NNP to_TO be_VB credited_VBN against_IN tax_NN payable_JJ in_IN the_DT UK_NNP ._.
179_CD GlaxoSmithKline_NNP Cross_NNP reference_NN to_TO Form_NN 20-F_NN This_DT table_NN has_VBZ been_VBN provided_VBN as_IN a_DT cross_NN reference_NN from_IN the_DT information_NN included_VBD in_IN this_DT Annual_JJ Report_NNP to_TO the_DT requirements_NNS of_IN Form_NN 20-F_NN ._.
Item_NN Page_NNP Item_NNP Page_NNP 8_CD Financial_NNP information_NN 1_CD Identity_NN of_IN directors_NNS ,_, senior_JJ management_NN and_CC advisors_NNS n_VBP a_DT A_DT Consolidated_NNP statements_NNS and_CC other_JJ financial_JJ information_NN 2_CD Offer_NN statistics_NNS and_CC expected_VBN timetable_NN n_NN a_DT Financial_NNP statements_NNS See_VB Item_NNP 18_CD 3_CD Key_NNP information_NN Legal_NNP proceedings_NNS 116-122_CD A_DT Selected_VBN financial_JJ data_NNS 160-162_CD ,174_CD B_NNP Significant_NNP changes_VBZ D_NNP Risk_NNP factors_NNS 76-78_CD Note_NN 31_CD Post_NNP Balance_NNP Sheet_NNP Event_NNP 122_CD 4_CD Information_NN on_IN the_DT company_NN 9_CD The_DT offer_NN and_CC listing_NN A_DT History_NN and_CC development_NN of_IN the_DT company_NN Inside_IN front_NN cover_NN A_DT Share_NN price_NN history_NN 176_CD B_NNP Business_NNP overview_VBD C_NNP Markets_NNP 176_CD Products_NNPS 25-26_CD ,28_CD 10_CD Additional_JJ information_NN Competition_NN 27-28_CD B_NNP Memorandum_NNP and_CC Articles_NNPS of_IN Association_NNP Footnote_NNP i_FW Regulation_NNP 29-30_CD C_NNP Material_NNP contracts_NNS n_VBP a_DT Marketing_NNP and_CC distribution_NN 18,23_CD D_NNP Exchange_NNP controls_VBZ 177_CD Manufacture_NN and_CC supply_NN 24_CD E_NNP Taxation_NNP 178_CD Research_NNP and_CC development_NN 07-17_CD H_NNP Documents_NNS on_IN display_NN 177_CD Intellectual_NNP property_NN 30-31_CD 11_CD Quantitative_JJ and_CC qualitative_JJ disclosures_NNS about_IN market_NN risk_NN Environment_NNP ,_, health_NN and_CC safety_NN 31-32_CD Treasury_NNP policies_NNS 74-75_CD Access_NNP to_TO medicines_NNS 19_CD Note_NN 34_CD -_: Financial_NNP instruments_NNS and_CC related_VBN disclosures_NNS 125-128_CD Investment_NN in_IN communities_NNS 21-22_CD C_NNP Organisational_NNP structure_NN 150-152_CD 12_CD Description_NN of_IN securities_NNS other_JJ than_IN equity_NN securities_NNS n_VBP a_DT D_NNP Property_NNP ,_, plants_NNS and_CC equipment_NN 71_CD 13_CD Defaults_NNS ,_, dividend_NN arrearages_NNS and_CC delinquencies_NNS n_VBP a_DT Environmental_JJ responsibility_NN 71_CD 14_CD Material_NNP modifications_NNS to_TO the_DT rights_NNS of_IN security_NN holders_NNS Note_VBP 6_CD Segment_NNP information_NN 100-102_CD and_CC use_NN of_IN proceeds_NNS n_VBP a_DT Note_NN 17_CD Tangible_JJ fixed_JJ assets_NNS 109_CD 15_CD Controls_NNP and_CC procedures_NNS 39-42_CD 5_CD Operating_NN and_CC financial_JJ review_NN and_CC prospects_NNS A_DT Operating_NN results_NNS 16_CD -LRB-_-LRB- Reserved_VBN -RRB-_-RRB- 2004_CD and_CC 2003_CD 61-78_CD A_DT Audit_NNP Committee_NNP financial_JJ expert_NN 40_CD 2003_CD and_CC 2002_CD 79-86_CD B_NNP Code_NNP of_IN ethics_NNS 41_CD B_NNP Liquidity_NN and_CC capital_NN resources_NNS 71-75_CD C_NNP Principal_NN accountant_NN fees_NNS and_CC services_NNS 104_CD C_NNP Research_NNP and_CC development_NN ,_, patents_NNS and_CC licenses_NNS ,_, etc._FW ._.
07-17_CD ,60_CD D_NNP Exemptions_NNS from_IN the_DT listing_NN standard_NN for_IN audit_NN committees_NNS n_VBP a_DT D_NNP Trend_NNP information_NN 60_CD E_NNP Purchases_NNPS of_IN equity_NN securities_NNS by_IN the_DT issuer_NN and_CC affiliated_VBN E_NNP Balance_NNP sheet_NN arrangements_NNS n_VBP a_DT purchasers_NNS 114_CD F_NN Tabular_JJ disclosure_NN of_IN contractual_JJ obligations_NNS 72_CD 17_CD Financial_NNP statements_NNS n_VBP a_DT 6_CD Directors_NNS ,_, senior_JJ management_NN and_CC employees_NNS 18_CD Financial_NNP statements_NNS A_DT Directors_NNS and_CC senior_JJ management_NN 34-35_CD Independent_NNP auditors_NNS report_VBP Footnote_NNP ii_FW B_NNP Compensation_NNP Consolidated_NNP statement_NN of_IN profit_NN and_CC loss_NN 90-91_CD Remuneration_NNP Report_NNP 43-58_CD Consolidated_NNP statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC C_NNP Board_NNP practices_NNS losses_NNS 90-91_CD Corporate_JJ governance_NN 36-42_CD Consolidated_NNP statement_NN of_IN cash_NN flow_NN 92-93_CD D_NNP Employees_NNP Consolidated_NNP balance_NN sheet_NN 94_CD GlaxoSmithKline_NNP people_NNS 20_CD Reconciliation_NNP of_IN movements_NNS in_IN consolidated_JJ equity_NN Note_NN 35_CD Employee_NN costs_NNS 129-135_JJ shareholders_NNS funds_NNS 94_CD Financial_NNP record_NN 162_CD Company_NN balance_NN sheet_NN 95_CD E_NNP Share_NNP ownership_NN Notes_NNS to_TO the_DT financial_JJ statements_NNS 96-152_CD GlaxoSmithKline_NNP people_NNS 20_CD 19_CD Exhibits_NNPS Footnote_NNP ii_FW Note_NN 36_CD Employee_NN share_NN schemes_NNS 136-138_CD Share_NN options_NNS 54-55_CD Footnote_NNP Incentive_NNP plans_VBZ 55-56_CD i_FW Information_NN responsive_JJ to_TO this_DT item_NN is_VBZ incorporated_VBN by_IN reference_NN Directors_NNS interests_NNS 53,58_CD to_TO Memorandum_NNP and_CC Articles_NNPS of_IN Association_NNP of_IN GlaxoSmithKline_NNP 7_CD Major_JJ shareholders_NNS and_CC related_VBN party_NN transactions_NNS at_IN pages_NNS 3536_CD of_IN the_DT Groups_NNS Annual_JJ Report_NNP on_IN Form_NN 20-F_NN for_IN the_DT year_NN ended_VBD 31st_CD December_NNP 2000_CD ._.
A_DT Major_JJ shareholders_NNS 177_CD B_NNP Related_VBN party_NN transactions_NNS ii_VBP See_VB the_DT companys_NNS Form_NN 20-F_JJ filing_NN with_IN the_DT Securities_NNPS and_CC Exchange_NNP Note_VBP 32_CD Related_JJ party_NN transactions_NNS 122_CD Commission_NNP ._.
